PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Genome-wide DNA methylation measurements in prostate tissues uncovers novel prostate cancer diagnostic biomarkers and transcription factor binding patterns.

Abstract Current diagnostic tools for prostate cancer lack specificity and sensitivity for detecting very early lesions. DNA methylation is a stable genomic modification that is detectable in peripheral patient fluids such as urine and blood plasma that could serve as a non-invasive diagnostic biomarker for prostate cancer.
PMID
Related Publications

Chromosome-wide mapping of DNA methylation patterns in normal and malignant prostate cells reveals pervasive methylation of gene-associated and conserved intergenic sequences.

Deregulation of an imprinted gene network in prostate cancer.

Epigenomic profiling of DNA methylation in paired prostate cancer versus adjacent benign tissue.

Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer.

DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer.

Authors

Mayor MeshTerms

DNA Methylation

Keywords

Biomarker

DNA methylation

Diagnostic

EZH2

Prostate cancer

Journal Title bmc cancer
Publication Year Start




PMID- 28412973
OWN - NLM
STAT- MEDLINE
DA  - 20170417
DCOM- 20170418
LR  - 20170422
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 17
IP  - 1
DP  - 2017 Apr 17
TI  - Genome-wide DNA methylation measurements in prostate tissues uncovers novel
      prostate cancer diagnostic biomarkers and transcription factor binding patterns.
PG  - 273
LID - 10.1186/s12885-017-3252-2 [doi]
AB  - BACKGROUND: Current diagnostic tools for prostate cancer lack specificity and
      sensitivity for detecting very early lesions. DNA methylation is a stable genomic
      modification that is detectable in peripheral patient fluids such as urine and
      blood plasma that could serve as a non-invasive diagnostic biomarker for prostate
      cancer. METHODS: We measured genome-wide DNA methylation patterns in 73
      clinically annotated fresh-frozen prostate cancers and 63 benign-adjacent
      prostate tissues using the Illumina Infinium HumanMethylation450 BeadChip array. 
      We overlaid the most significantly differentially methylated sites in the genome 
      with transcription factor binding sites measured by the Encyclopedia of DNA
      Elements consortium. We used logistic regression and receiver operating
      characteristic curves to assess the performance of candidate diagnostic models.
      RESULTS: We identified methylation patterns that have a high predictive power for
      distinguishing malignant prostate tissue from benign-adjacent prostate tissue,
      and these methylation signatures were validated using data from The Cancer Genome
      Atlas Project. Furthermore, by overlaying ENCODE transcription factor binding
      data, we observed an enrichment of enhancer of zeste homolog 2 binding in gene
      regulatory regions with higher DNA methylation in malignant prostate tissues.
      CONCLUSIONS: DNA methylation patterns are greatly altered in prostate cancer
      tissue in comparison to benign-adjacent tissue. We have discovered patterns of
      DNA methylation marks that can distinguish prostate cancers with high specificity
      and sensitivity in multiple patient tissue cohorts, and we have identified
      transcription factors binding in these differentially methylated regions that may
      play important roles in prostate cancer development.
FAU - Kirby, Marie K
AU  - Kirby MK
AD  - HudsonAlpha Institute for Biotechnology, 601 Genome Way, Huntsville, AL, 35806,
      USA.
AD  - Present Address: TRM Oncology, 5901-C Peachtree Dunwoody Rd, Suite 200, Atlanta, 
      GA, 30328, USA.
FAU - Ramaker, Ryne C
AU  - Ramaker RC
AD  - HudsonAlpha Institute for Biotechnology, 601 Genome Way, Huntsville, AL, 35806,
      USA.
AD  - Department of Genetics, Kaul Human Genetics Building, Suite 230, 720 20th Street 
      South, Birmingham, AL, 35294, USA.
FAU - Roberts, Brian S
AU  - Roberts BS
AD  - HudsonAlpha Institute for Biotechnology, 601 Genome Way, Huntsville, AL, 35806,
      USA.
FAU - Lasseigne, Brittany N
AU  - Lasseigne BN
AD  - HudsonAlpha Institute for Biotechnology, 601 Genome Way, Huntsville, AL, 35806,
      USA.
FAU - Gunther, David S
AU  - Gunther DS
AD  - HudsonAlpha Institute for Biotechnology, 601 Genome Way, Huntsville, AL, 35806,
      USA.
AD  - Present Address: University of Southern California, University Park, Los Angeles,
      CA, 90089, USA.
FAU - Burwell, Todd C
AU  - Burwell TC
AD  - HudsonAlpha Institute for Biotechnology, 601 Genome Way, Huntsville, AL, 35806,
      USA.
AD  - Present Address: Boeing Co., 499 Boeing Blvd, SW, Huntsville, AL, 35824, USA.
FAU - Davis, Nicholas S
AU  - Davis NS
AD  - HudsonAlpha Institute for Biotechnology, 601 Genome Way, Huntsville, AL, 35806,
      USA.
AD  - Present Address: Duke University, 101 Science Drive, Durham, NC, 27708, USA.
FAU - Gulzar, Zulfiqar G
AU  - Gulzar ZG
AD  - Department of Urology, Stanford University Medical Center, Room S287, 300 Pasteur
      Drive, Stanford, CA, 94305-5118, USA.
AD  - Present Address: NuGEN technologies, 201 Industrial Rd #310, San Carlos, CA,
      94070, USA.
FAU - Absher, Devin M
AU  - Absher DM
AD  - HudsonAlpha Institute for Biotechnology, 601 Genome Way, Huntsville, AL, 35806,
      USA.
FAU - Cooper, Sara J
AU  - Cooper SJ
AD  - HudsonAlpha Institute for Biotechnology, 601 Genome Way, Huntsville, AL, 35806,
      USA.
FAU - Brooks, James D
AU  - Brooks JD
AD  - Department of Urology, Stanford University Medical Center, Room S287, 300 Pasteur
      Drive, Stanford, CA, 94305-5118, USA. [email protected]
FAU - Myers, Richard M
AU  - Myers RM
AD  - HudsonAlpha Institute for Biotechnology, 601 Genome Way, Huntsville, AL, 35806,
      USA. [email protected]
LA  - eng
GR  - T32 GM008361/GM/NIGMS NIH HHS/United States
GR  - U01 CA196387/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20170417
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Transcription Factors)
RN  - 8J337D1HZY (Cytosine)
RN  - EC 2.1.1.43 (EZH2 protein, human)
RN  - EC 2.1.1.43 (Enhancer of Zeste Homolog 2 Protein)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/*genetics/metabolism
MH  - Cytosine/metabolism
MH  - *DNA Methylation
MH  - Enhancer of Zeste Homolog 2 Protein/genetics/metabolism
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prostatic Neoplasms/*genetics/metabolism/pathology
MH  - Prostatic Neoplasms, Castration-Resistant/genetics/metabolism
MH  - Transcription Factors/*genetics/metabolism
PMC - PMC5392915
OTO - NOTNLM
OT  - Biomarker
OT  - DNA methylation
OT  - Diagnostic
OT  - EZH2
OT  - Prostate cancer
EDAT- 2017/04/18 06:00
MHDA- 2017/04/19 06:00
CRDT- 2017/04/18 06:00
PHST- 2016/01/30 [received]
PHST- 2017/04/01 [accepted]
AID - 10.1186/s12885-017-3252-2 [doi]
AID - 10.1186/s12885-017-3252-2 [pii]
PST - epublish
SO  - BMC Cancer. 2017 Apr 17;17(1):273. doi: 10.1186/s12885-017-3252-2.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>